// App-Quantinova.ai

: Ixekizumab achieved and sustained nail psoriasis resolution regardless of disease severity through 5 years: Results from Uncover-3

Researchers

Presenter

  • Alexander Egeberg

Principal Investigators

  • Lars Erik Kristensen

  • Ronald Vender

  • Shirin Zaheri

  • Celine El Baou

  • Gaia Gallo

  • Elisabeth Riedl

  • Christopher Schuster

Medical Centers

  • Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

  • The Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark

  • Department of Medicine, Division of Dermatology, McMaster University, Dermatrials Research Inc, Hamilton, Canada

  • Imperial College Healthcare NHS Trust, London,

  • Eli Lilly and Company, Indianapolis, IN

  • Department of Urology, Medical University Vienna, Vienna, Austria

Locations

  • Denmark

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT01646177

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved